Skip to main content
. 2021 Apr 8;6(7):e142205. doi: 10.1172/jci.insight.142205

Figure 3. JAK3-selective inhibitor treatment prevented the onset of AA.

Figure 3

C3H/HeJ grafted mice were given PF-06651600 (JAK3i) at a dosage of 30 mg/kg for 4 weeks. (A) Survival curve analysis depicts the hair loss between JAK3i- and control-treated mice. ***P < 0.01, log-rank test. (B) Representative immunofluorescence images of skin sections from JAK3i- or control-treated mice, stained with anti-CD8, anti–MHC class I, or anti–MHC class II mAbs. Scale bar: 200 μm. (C) Representative FACS plots of the skin single cell in the viable cell gate were acquired for each sample. (D) Summary graphs of the percentages of CD44+CD62L–CD8+ T cells as well as NKG2D+CD8+ T cells within the skin after treatment. ***P < 0.001 (unpaired Student’s t test). (E) Representative FACS plots of SDLNs in the viable cell gate were acquired for each sample. (F) Summary graphs of the percentages of CD44+CD62L–CD8+ T cells as well as NKG2D+CD8+ T cells within the SDLNs after treatment. ***P < 0.001 (unpaired Student’s t test). Two replicate experiments were performed for 10 mice per group.